Acute bacterial skin and skin structure infections are common types of skin diseases that require prompt treatment to prevent further complications. These include infections like cellulitis, cutaneous abscesses, and infected wounds. Antibiotics are the most common treatment option for such types of infections. Some of the commonly used antibiotics are cephalosporins, carbapenems, fluoroquinolones, and oxazolidinones.
The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rise in hospital acquired infections has been a major driver of growth for the acute bacterial skin and skin structure infections market. Hospital acquired infections, also known as nosocomial infections, develop 48–72 hours or more after hospital admission or medical treatment. These infections often affect elderly patients and those with long-term hospital stays. With growing geriatric population and increasing incidence of chronic diseases that require long-term hospitalization, the risk of hospital acquired skin infections has increased significantly. According to the Centers for Disease Control and Prevention, around 1 in 25 hospital patients contracts at least one hospital acquired infection. This has augmented the demand for effective treatment options like antibiotics, thereby fueling market growth.
SWOT Analysis
Strength: Acute bacterial skin and skin structure infections have a high prevalence and effective treatment options are available. Antibiotics have shown success in treating such infections.
Weakness: Resistance to commonly used antibiotics is growing. This poses a challenge in effective treatment. Short duration of illness limits treatment opportunities.
Opportunity: Increasing research investment to develop novel treatment approaches. Growing awareness about appropriate antibiotic use can curb resistance development.
Threats: Global burden of antibiotic resistance threatens treatment success. Social and economic costs of infections pose challenges.
Key Takeaways
The global Acute Bacterial Skin and Skin Structure Infections market is expected to witness high growth.
The North America region currently dominates the market and is expected to continue its dominance over the forecast period. This can be attributed to factors such as growing prevalence of infections, strong healthcare infrastructure and availability of cutting edge treatment options. However, the Asia Pacific region is poised to witness fastest growth owing to rising population, improving access to healthcare and increasing expenditure on healthcare.
Key players related content comprises Key players operating in the Acute Bacterial Skin and Skin Structure Infections are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it